文献速递神经外周血管介入DSAUS

药物涂层球囊血管成形术治疗椎动脉起始部狭窄的回顾性研究

A retrospective study of drug-coated balloon angioplasty for vertebral artery origin stenosis.
PubMed 文献 · Neuroradiology · 2022-03-08

本研究纳入2018年4月至2019年12月间20例严重症状性椎动脉起始部狭窄患者,单独使用药物涂层球囊(DCB)治疗,评估其可行性、安全性和有效性。16例成功完成DCB扩张,4例因需补救性支架置入而排除;术后30天内无不良事件发生。随访期间超声检出3例(18.8%)椎动脉起始部再狭窄,其中2例属于残余狭窄较高组,提示残余狭窄程度可能影响再狭窄率。

要点

  • DCB治疗严重椎动脉起始部狭窄术后30天内无血管性死亡、TIA或卒中发生。
  • 16例成功DCB扩张者中,随访超声检出3例(18.8%)椎动脉起始部再狭窄。
  • 再狭窄的3例中2例属于残余狭窄≥50%但<70%组,提示残余狭窄越重再狭窄率可能越高。

核心结论

  • 单独使用DCB治疗椎动脉起始部狭窄可能可行、安全且有效,DCB后的残余狭窄程度可能影响再狭窄率。

研究设计与样本

  • 回顾性研究,纳入2018年4月至2019年12月间20例严重椎动脉起始部狭窄患者,均单独使用DCB治疗;主要终点为术后30天内责任动脉相关的血管性死亡、短暂性脑缺血发作(TIA)和卒中,次要终点为随访时再狭窄、晚期TIA和卒中及改良Rankin量表(mRS)≤2的满意临床结局。

诊断标准与关键数值

  • 术后残余椎动脉起始部狭窄(rVAOS)<50%者为较低rVAOS组(10/16例),rVAOS≥50%但<70%者为较高rVAOS组(6/16例)。
  • 随访期间通过超声检出椎动脉起始部再狭窄3例(18.8%,3/16)。
  • 再狭窄的3例中2例属于较高rVAOS组。
  • 随访中位时间7个月(四分位距1-18个月),所有患者在整个随访期间无主诉。

局限性

  • 4例因需进一步补救性支架置入而被排除。
  • 作者指出DCB治疗椎动脉起始部狭窄的获益尚不确定。
  • 再狭窄率与残余狭窄程度的关系仅为可能趋势,原文表述为「might indicate a tendency」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Angioplasty using drug-coated balloon (DCB) for treatment of symptomatic vertebral artery origin stenosis (VAOS) is promising, but of uncertain benefit. This study aimed to evaluate the feasibility, safety, and effectiveness of using DCB in the treatment of severe VAOS.

METHODS: This study included 20 patients with severe VAOS treated with DCB alone between April 2018 and December 2019. Vascular death, transient ischemic attack (TIA), and stroke related to the responsible artery within 30 days after procedure were recorded as primary endpoints. Restenosis, late TIA, and stroke related to VAOS and satisfied clinical outcome [modified Rankin Scale (mRS) ≤ 2] were documented at follow-up visit as secondary endpoints.

RESULTS: Of 20 patients, 16 were performed DCB dilation successfully, and 4 were excluded due to further bailout stenting. After the procedure, no adverse event occurred within 30 days. Ten of 16 patients achieved residual VAOS (rVAOS) < 50% (lower rVAOS group), and the remaining 6 patients achieved rVAOS ≥ 50% but < 70% (higher rVAOS group). During follow-up, vertebral artery origin restenosis was detected in 3 (18.8%) of 16 patients by ultrasound. Among the 3 patients with restenosis, 2 were belonged to the higher rVAOS group, which might indicate a tendency that the more severe the residual stenosis, the higher the restenosis rate. All patients had no complaint in the whole follow-up period (median, 7 months; InterQuartile Range, 1-18 months).

CONCLUSIONS: Angioplasty using DCB for VAOS may be feasible, safe, and effective. The degree of residual stenosis after using DCB alone may affect the restenosis rate.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Zhao, Yan, Wang, et al. A retrospective study of drug-coated balloon angioplasty for vertebral artery origin stenosis. Neuroradiology. 2022. PMID: 35257205. doi:10.1007/s00234-022-02926-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。